Illumina’s Non-Invasive verifi® Prenatal Test Using cfDNA Significantly Reduces False Positive Rate of Fetal Aneuploidy Detection Compared to Current Standard Pregnancy Screening Practices

[Business Wire] – Illumina, Inc. today announced that in a direct comparison of non-invasive prenatal testing using cell free DNA to standard prenatal aneuploidy screening in a general obstetrical population, the verifi® prenatal test1 significantly red more

View todays social media effects on ILMN

View the latest stocks trending across Twitter. Click to view dashboard

See who Illumina is hiring next, click here to view